Regarding the similar role of CCL2 in the pathogenesis of RA and OA, CCN1 inhibition could serve as a potential strategy via reducing the CCL2/CCR2 axis-mediated inflammation in these bone and cartilage disorders (98). This evidence concerns the gene CCN1 and rheumatoid arthritis.